Thymosin Alpha-1
A thymic peptide approved in multiple countries for immune modulation, particularly in hepatitis and as a vaccine adjuvant.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid peptide that is naturally produced by the thymus gland. It plays a central role in immune system maturation and regulation. The synthetic version (Zadaxin/Thymalfasin) is approved in over 35 countries for the treatment of hepatitis B and C, and as a vaccine adjuvant. It is not FDA-approved in the United States but is available through compounding pharmacies.
Why People Talk About It
Immune system modulation
StrongHepatitis B and C treatment (approved internationally)
StrongVaccine response enhancement
ModerateImmune support during illness
EmergingHow It Works
Thymosin Alpha-1 helps train and regulate your immune system. It supports the maturation of T-cells (key immune fighters) and helps balance the immune response — boosting it when needed and calming it when overactive.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Not FDA-approved in the US
- • Should be used under clinician guidance
- • May not be appropriate for those on immunosuppressive therapy without careful monitoring
What We Don't Know
While extensively studied internationally, some applications discussed in the wellness space go beyond the studied indications.
Published Research
32 studiesThymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted
Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection
[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis]
Thymic peptides for treatment of cancer patients
Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial
A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report
Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial
The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study
Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma
Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B
A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1
[Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial]
Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study
Thymosin alpha 1 provides short-term and long-term benefits in the reimplantation of avulsed teeth: a double-blind randomized control pilot study
Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria
[The prophylactic effect of thymosin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease]
Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study
Thymosin alpha 1: A comprehensive review of the literature
Immune Modulation with Thymosin Alpha 1 Treatment
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Research Insights
Related Peptides
Quick Facts
- Class
- Thymic Peptide
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Feb 2026
- Citations
- 32PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician